US Pat. No. 9,194,003

MITF AS A MARKER FOR PREDISPOSITION TO CANCER

INSTITUT GUSTAVE ROUSSY, ...

1. A method for determining whether a subject has a predisposition or a susceptibility to develop a cancer selected from a
cutaneous malignant melanoma or a renal cancer, the method comprising (1) detecting in a biological sample obtained from said
subject a germline mutation in microphthalmia-associated transcription factor (MITF) gene that causes the substitution of
the E318 residue with a Lysine residue (the E318K mutation) in the MITF protein, said detecting step comprising contacting
said sample with an oligonucleotide whose nucleotide sequence comprises the sequence of SEQ ID NO: 29 or contacting said sample
with an oligonucleotide whose nucleotide sequence comprises the sequence of SEQ ID NO: 30 and an oligonucleotide whose nucleotide
sequence comprises the sequence of SEQ ID NO: 29 and (2) diagnosing the predisposition or the susceptibility to develop cutaneous
malignant melanoma or renal cancer in a subject identified as having the germline E318K mutation.
US Pat. No. 9,557,333

METHODS OF TREATING GASTROINTESTINAL SARCOMA PATIENTS DEPENDING ON THEIR SB7H6 SERUM LEVEL

INSTITUT GUSTAVE ROUSSY, ...

1. A method of treating a gastrointestinal sarcoma (GIST) in a subject, the method comprising the steps of:
a) determining, in a biological sample of said subject, the expression level of soluble B7H6 (sB7H6) and the presence or absence
of soluble MIC (sMIC) in an enzyme linked immunosorbent assay (ELISA);

b) comparing said expression level of sB7H6 in the biological sample of the subject to a sB7H6 reference expression level
in an ELISA; and

c) treating GIST in the subject by administering to the subject:
i) imatinib in combination with an appropriate chemotherapeutic treatment when:
a) the expression level of sB7H6 in the biological sample of the subject is above the sB7H6 reference expression level of
about 3 ng/ml, or

b) the expression level of sB7H6 in the biological sample of the subject is above the sB7H6 reference expression level of
about 3 ng/ml and sMIC is absent in the biological sample of the subject: or

ii) imatinib alone when:
a) the expression level of sB7H6 in the biological sample of the subject is below the sB7H6 reference expression level of
about 3 ng/ml, or

b) the expression level of sB7H6 in the biological sample of the subject is below the sB7H6 reference expression level of
about 3 ng/ml and sMIC is present in the biological sample of the subject;

wherein the appropriate chemotherapeutic treatment comprises an anti-B7-H6 neutralizing antibody and an immunomodulator stimulating
T and/or NK cell production or activity, and

wherein the sB7H6 reference expression level is the level of the sB7H6 polypeptide in one or more control samples derived
from one or more individuals having GIST.

US Pat. No. 9,682,137

MUTANT HUMAN AND SIMIAN IMMUNODEFICIENCY VIRUS ENV PROTEINS WITH REDUCED IMMUNOSUPPRESSIVE PROPERTIES

VIROXIS SAS, Paris (FR) ...


wherein,
X represents any amino acid,and either
Xa is A, F, G, L or R, and Xb is any amino acid,

Xa is any amino acid, and Xb is A, F, G or R, or

Xa is A, F, G, L or R, and Xb is A, F, G or R,

in association with a pharmaceutically acceptable carrier,
said no or reduction of immunosuppressive activity of the above mentioned mutated human or simian lentiviral ENV protein or
of the above defined fragment being liable to be assessed by the fact that in an in vivo assay involving engrafted tumor cells
rejection,

said tumor cells being transduced either so as to express said mutated ENV protein or said fragment (mutated ENV tumor cells),
or said tumor cells being transduced so as to express the corresponding wild type non-mutated ENV protein or a fragment thereof
(wild type ENV tumor cells),

or said tumor cells being not transduced (normal tumor cells),
the following ratio:
immunosuppression index of said mutated ENV protein or of said fragment (imutated env)/immunosuppression index of wild type ENV protein (iwild type env) is less than 0.5,

imutated env being defined by: (maximum area reached by mutated ENV tumor cells?maximum area reached by normal tumor cells)/(maximum area
reached by normal tumor cells), and

iwild type env being defined by: (maximum area reached by wild type ENV tumor cells?maximum area reached by normal tumor cells)/(maximum
area reached by normal tumor cells).

US Pat. No. 9,593,376

NATURAL KILLER P30 (NKP30) DYSFUNCTION AND THE BIOLOGICAL APPLICATIONS THEREOF

INSTITUT GUSTAVE ROUSSY, ...

1. A method of treating a human subject having a gastrointestinal stromal tumor (GIST), the method comprising
measuring the relative amount of NKp30c, NKp30b, and NKp30a RNA transcript isoforms in a natural killer (NK) cell sample or
in a peripheral mononuclear cell sample comprising NK cells obtained from the human subject;

detecting a higher amount of NKp30c RNA transcript isoform than NKp30b and NKp30a RNA transcript isoforms in said NK cell
sample or said peripheral mononuclear cell sample comprising NK cells; and

administering to the human subject having a higher amount of NKp30c RNA transcript isoform a pharmaceutical composition comprising
trichostatin A (TSA) or 5-azacitidine.

US Pat. No. 9,428,530

DERIVATIVES OF OXAZAPHOSPHORINES THAT ARE PRE-ACTIVATED, USE AND METHOD OF PREPARATION

INSTITUT GUSTAVE ROUSSY, ...

1. A compound of formula (I)

wherein:
X is O or S;
R1, and R2 are independently H, —(CH2)2—Cl or —CH(CH3)—CH2—Cl with proviso that at least one group among R1 and R2 is —(CH2)2—Cl or —CH(CH3)—CH2—Cl;

R3 is —(CH2)2—Cl or —CH(CH3)—CH2—Cl;

R4 is a vectorization or formulation group comprising a linear or branched, unsaturated hydrocarbon group of 5 to 30 carbon
atoms, optionally substituted by one or more substituents selected from —OR, —C(O)OR, —OC(O)R, —OC(O)OR, —C(O)R, —NRR?, —C(O)NRR?,
—NC(O)R, —NRC(O)R?, —SR, halogen, cyano (—CN), aryl, heteroaryl, alkyl and arylalkyl, wherein R is hydrogen or a C1-C3 alkyl and R? is hydrogen or a C1-C3 alkyl;

or a pharmaceutically acceptable salt thereof.
US Pat. No. 9,810,692

METHODS FOR PREDICTING THE SENSITIVITY OF A SUBJECT TO IMMUNOTHERAPY

INSTITUT GUSTAVE ROUSSY, ...

1. An in vitro method of assessing the sensitivity of a subject having melanoma to an immunotherapeutic molecule acting on
the subject's T cells for treating melanoma, which method comprises a step a) of determining, in a biological sample from
said subject selected from a blood, a serum, a plasma sample or a derivative thereof, the respective basal expression levels
of soluble CD25 (sCD25) and of lactic acid dehydrogenase (LDH), and, when the sCD25 and LDH expression levels are determined,
a step b) of comparing said sCD25 and LDH basal levels of expression to sCD25 and LDH, respectively, thereby assessing whether
the subject having a tumor is sensitive or resistant to the immunotherapeutic molecule, wherein the immunotherapeutic molecule
is an anti-CTLA-4 antibody and:
when the LDH reference expression level is about 500 IU, the step of assessing whether the subject having melanoma is sensitive
or resistant to the immunotherapeutic molecule comprises:

i) identifying the subject as having melanoma that is resistant to the immunotherapeutic molecule based on the sCD25 basal
expression level being above the sCD25 reference expression level and/or the LDH basal expression level being above the LDH
reference expression level of about 500 IU; or

ii) identifying the subject as having melanoma that is sensitive to the immunotherapeutic molecule based on the sCD25 basal
expression level being below the sCD25 reference expression level together with the LDH basal expression level being below
the LDH reference expression level of about 500 IU; and

iii) administering therapeutic doses of an anti-CTLA-4 antibody to the subject identified as having a melanoma that is sensitive
to the immunotherapeutic molecule, or

iv) administering therapeutic doses of an anti-CTLA-4 antibody in combination with therapeutic doses of a compensatory molecule
selected from interleukin-2 (IL-2), interleukin-15 (IL-15), IL-2 superkine, sushi IL-15, radioimmunoconjugate of anti-CD25
and immunotoxin or a combination of the compensatory molecules to the subject identified as having a melanoma that is resistant
to the immunotherapeutic molecule.

US Pat. No. 9,974,852

MUTATED NON-PRIMATE LENTIVIRAL ENV PROTEINS AND THEIR USE AS DRUGS

VIROXIS SAS, Paris (FR) ...

wherein,X1 is A or R, and X2, X3, X4 and X5 are any amino acid, or
X2 is A or R, and X1, X3, X4 and X5 are any amino acid, or
X3 is A or R, and X1, X2, X4 and X5 are any amino acid, or
X4 is A or R, and X1, X2, X3 and X5 are any amino acid, or
X5 is A or R, and X1, X2, X3 and X4 are any amino acid,in association with a pharmaceutically acceptable carrier.

US Pat. No. 9,073,957

DERIVATIVES OF OXAZAPHOSPHORINES THAT ARE PRE-ACTIVATED, USE AND METHOD OF PREPARATION

INSTITUT GUSTAVE ROUSSY, ...

1. A compound of formula (I)

wherein
X is O or S;
R2 is H;
R1 and R3 are independently —(CH2)2—Cl or —CH(CH3)—CH2—Cl; and

R4 is a formulation or vectorization group comprising:
a linear or branched unsaturated hydrocarbon group of 5 to 30 carbon atoms, optionally substituted by one or more groups selected
from the group consisting of —OR, —C(O)OR, —OC(O)R, —OC(O)OR, —C(O)R, —NRR?, —C(O)NRR?, —NC(O)R, —NRC(O)R?, —SR, halogen,
cyano (—CN), aryl, heteroaryl, alkyl and arylalkyl;

R is hydrogen or a C1-C3 alkyl and

R? is hydrogen or a C1-C3 alkyl;

or a pharmaceutically acceptable salt thereof.

US Pat. No. 10,125,157

DERIVATIVES OF OXAZAPHOSPHORINES THAT ARE PRE-ACTIVATED, USE AND METHOD OF PREPARATION

INSTITUT GUSTAVE ROUSSY, ...

1. A compound of formula (I)
wherein:
X is O;
R1 and R3 are both —(CH2)2—CI;
R2 is H; and
R4 is a linear or branched, saturated, hydrocarbon chain of 5 to 30 carbon atoms;
or a pharmaceutically acceptable salt thereof.
US Pat. No. 9,938,528

METHODS AND PHARMACEUTICAL COMPOSITIONS FOR TREATING HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 (HIV-1) INFECTIONS

INSTITUT NATIONAL DE LA S...

1. A method for treating HIV-1 infection in a subject in need thereof comprising administering to the subject a therapeutically effective amount of an inhibitor of suppressor of G2 allele of SKP1 (SGT1) activity or expression.
US Pat. No. 9,862,931

ADENOVIRUS VACCINE VECTORS

Institut Gustave Roussy, ...

1. A method of generating a humoral immune response against one or more target B-cell epitope(s) in a subject having a pre-existing
humoral immunity against an adenovirus of a given serotype resulting from a previous exposure to a wild-type or recombinant
adenovirus, comprising:
administering to the subject a recombinant replication-defective adenovirus of the same serotype,
wherein the subject has pre-existing humoral immunity to the same adenovirus serotype of said replication-defective adenovirus;
said replication defective adenovirus has a heterologous polypeptide of up to 50 amino acids containing one or more target
B-cell epitope(s) from a foreign antigen of interest inserted into the HI loop of the knob of a fiber protein of the replication-defective
adenovirus, and an IgG humoral immune response against the target B-cell epitope(s) in the subject is enhanced by a pre-existing
humoral immunity against said adenovirus serotype.

US Pat. No. 10,646,521

MICROBIOTA COMPOSITION, AS A MARKER OF RESPONSIVENESS TO CHEMOTHERAPY, AND USE OF MICROBIAL MODULATORS (PRE-, PRO- OR SYNBIOTICS) FOR IMPROVING THE EFFICACY OF A CANCER TREATMENT

INSTITUT GUSTAVE ROUSSY, ...

1. A method of treating cancer in a human subject in need thereof, comprising administering to the subject: (a) a probiotic composition comprising an amount of an Enterococcus hirae strain; and (b) dose(s) of an alkylating chemotherapeutic agent, wherein the administering of the probiotic composition and the alkylating chemotherapeutic agent to the subject induces a T-bet/Th1 local and systemic immune response, thereby treating the cancer in the subject.

US Pat. No. 10,098,901

DERIVATIVES OF OXAZAPHOSPHORINES AND THERAPEUTIC USES THEREOF

INSTITUT GUSTAVE ROUSSY, ...

1. A compound of formula (I):wherein:A is selected from the group consisting of:
O, S, —O—(C?S)—S—, —ONH—, —ONR?—, —NR?O—, —NHO—,
Y1—(CH2)n—Y2, where n is an integer from 1 to 8, and
Y1—(CH2—CH2—O)a—CH2—CH2—Y2 where a is an integer from 1 to 5,
wherein Y1 and Y2 are independently selected from —O—, —NH—, —S—, —OC(O)—, —C(O)NH—, —NHC(O)—, —O—C(S)—S—, S—C(S)—O—NR?—, —ONH—, —NHO—, —ONR?—, —NR?O—, —OC(O)—O—, NR?C(S)S—, —SC(S)NR?—, —NR?C(O)—, —C(O)NR?— and —C(O)O—, and R? is a C1-C6 alkyl,
and wherein —R1, R2 and R3 are independently selected from the group consisting of —H, —CH(CH3)—CH2—X and —(CH2)2—X, X being a halogen atom,
or a pharmaceutically acceptable salt or solvate thereof.

US Pat. No. 11,110,105

COMPOUNDS, COMPOSITION AND USES THEREOF FOR TREATING CANCER

INSTITUT GUSTAVE ROUSSY, ...


1. A medicament comprising a compound of formula



wherein R1 and R2 are independently selected from the group consisting of Na, H, —CH3, —CH2—CH3, —CH2—CH?CH3, n-CH2—CH2—CH3, P(O)(O—CH2—CH3)2, P(O)(OH)2 or P(O)(ONa)2 and wherein R1, R2, R3, R4 and R5 are not H simultaneously, wherein R1 is not —CH3 when R2 is P(O)(ONa)2 or P(O)(OH)2 and each of R3, R4 and R5 is H, and wherein R1 is not —CH3 or H when R2 is —CH3 and each of R3, R4 and R5 is H; and
wherein R3, R4 and R5 are independently selected from the group consisting of H, CH3, —CH2—CH3, —CH2—CH?CH3, and CnH2n+1 with n=3?10.

US Pat. No. 10,969,380

SIMULTANEOUS DETECTION OF CANNIBALISM AND SENESCENCE AS PROGNOSTIC MARKER FOR CANCER

Institut Gustave Roussy, ...

1. An in vitro method for detecting cannibalism behavior of a cell, comprising:measuring expression level of p53, expression level of a N-terminal isoform of p53 that lacks N-terminal transactivating domain, expression level of p53?, or expression level of p53? in said cell, wherein measuring expression level comprises measuring mRNA level; and
measuring activity of purinergic P2Y2 receptor (P2Y2R) in said cell by determining the phosphorylation of Pyk2.
US Pat. No. 11,021,442

PROCESS FOR THE PREPARATION OF FREEZE-DRIED 2-[(3-AMINOPROPYL)AMINO] ETHANETHIOL FORMULATION

CLEVEXEL PHARMA, Paris (...

1. A process for the preparation of freeze-dried 2-[(3-aminopropyl) amino]ethanethiol comprising the following steps:a) the reaction of a solution of amifostine with a strong acid, to obtain a solution of 2-[(3-aminopropyl)amino]ethanethiol, and
b) the freeze-drying of the solution of 2-[(3-aminopropyl)amino]ethanethiol, with or without addition of excipients.
US Pat. No. 10,954,515

THERAPEUTIC METHODS, PRODUCTS AND COMPOSITIONS INHIBITING ZNF555

INSTITUT GUSTAVE ROUSSY, ...

1. A method for treating rhabdomyosarcoma in a subject comprising a step of transfecting said rhabdomyosarcoma with an inhibitory nucleic acid comprising SEQ ID NO: 46 to a subject in need of treatment.
US Pat. No. 10,899,838

ANTIBODY WHICH IS DIRECTED AGAINST GALECTIN-9 AND IS AN INHIBITOR OF THE SUPPRESSOR ACTIVITY OF REGULATORY T LYMPHOCYTES

Universite de Lille, Lil...

1. A method of treating nasopharyngeal carcinoma in a human patient in need thereof comprising administering to the human patient an amount of an antibody directed against Galectin-9 effective to inhibit the suppressor activity of human regulatory T lymphocytes, thereby reducing tumor growth in the human patient, wherein the antibody has as CDRsthe six CDRs defined by:
the amino acid sequence SEQ ID NO:2 in the region H-CDR1;
the amino acid sequence SEQ ID NO:3 in the region H-CDR2;
the amino acid sequence SEQ ID NO:4 in the region H-CDR3;
the amino acid sequence SEQ ID NO:6 in the region L-CDR1;
the amino acid sequence SEQ ID NO:7 in the region L-CDR2; and
the amino acid sequence SEQ ID NO:8 in the region L-CDR3.